Agios Pharmaceuticals, Inc.

344 articles about Agios Pharmaceuticals, Inc.

• Marc Tessier-Lavigne, Ph.D., President of The Rockefeller University, Joins Agios Pharmaceuticals Board of Directors

  9/20/2011

• Agios Pharmaceuticals Founder and Advisor Publish in Nature Genetics on Further Links Between Serine Metabolic Pathway and Cancer

  8/2/2011

• Agios Pharmaceuticals and Whitehead Institute Collaborate on Nature Publication Revealing Altered Metabolic Pathway in Breast Cancer

  7/15/2011

• Agios Pharmaceuticals to Present at 31st Annual Cowen and Company Healthcare Conference

  3/1/2011

• Agios Pharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference

  1/6/2011

• Agios Pharmaceuticals Announces Cancer Cell Publication of Research Illuminating Link between Cancer Metabolism and Epigenetics

  12/14/2010

• Agios Pharmaceuticals Awarded Two Federal Grants to Advance Cancer Metabolism Focused Therapeutics

  11/5/2010

• Agios Pharmaceuticals Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer

  9/20/2010

• Agios Pharmaceuticals Appoints John Maraganore, Ph.D., to Board of Directors

  6/24/2010

• Agios Pharmaceuticals Scientists Present IDH1 Data at 2010 American Association for Cancer Research Meeting

  4/21/2010

• Celgene and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism; Agios Will Receive $130 Million Upfront

  4/15/2010

• Agios Pharmaceuticals Appoints William Kaelin Jr., M.D. to Scientific Advisory Board

  3/11/2010

• Agios Pharmaceuticals Awarded Funding From Accelerate Brain Cancer Cure (ABC2) to Support Research into Novel Therapeutics and Diagnostics for Brain Cancer

  12/21/2009

• Agios Pharmaceuticals Publishes Groundbreaking Research in Nature Uncovering the New Role of IDH1 Gene Mutation in Brain Cancer

  11/23/2009

• Shanghai ChemPartner Co., Ltd. and Agios Pharmaceuticals Expand Cancer Drug Collaboration

  7/10/2009

• Shanghai ChemPartner Co., Ltd. and Agios Pharmaceuticals Expand Integrated Drug Discovery Research Collaboration

  7/9/2009

• Agios Pharmaceuticals' Focus of Drug Research – Cancer Metabolism – Selected for Stand Up To Cancer Grant

  5/28/2009

• Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO

  5/27/2009

• Agios Pharmaceuticals' Founders Author Science Review on Cancer Metabolism

  5/21/2009

• Agios Pharmaceuticals Highlights Extensive Cancer Metabolism Research at American Association for Cancer Research

  4/30/2009